| Item type |
学術雑誌論文 / Journal Article(1) |
| タイトル |
|
|
タイトル |
Progress of Therapeutic Antibodies in the Treatment of Patients with Multiple Myeloma and Possible Impacts of Antibodies on the Evaluation of Response to the Treatment |
|
言語 |
en |
| 言語 |
|
|
言語 |
jpn |
| キーワード |
|
|
言語 |
en |
|
主題Scheme |
Other |
|
主題 |
Multiple myeloma |
| キーワード |
|
|
言語 |
en |
|
主題Scheme |
Other |
|
主題 |
daratumumab |
| キーワード |
|
|
言語 |
en |
|
主題Scheme |
Other |
|
主題 |
CD38 |
| キーワード |
|
|
言語 |
en |
|
主題Scheme |
Other |
|
主題 |
elotuzumab |
| キーワード |
|
|
言語 |
en |
|
主題Scheme |
Other |
|
主題 |
SLAMF7 |
| 資源タイプ |
|
|
資源タイプ識別子 |
http://purl.org/coar/resource_type/c_6501 |
|
資源タイプ |
journal article |
| アクセス権 |
|
|
アクセス権 |
open access |
|
アクセス権URI |
http://purl.org/coar/access_right/c_abf2 |
| 著者 |
Imai, Yoichi
Handa, Tomoyuki
Mitani, Kinuko
|
| 書誌情報 |
en : Dokkyo Medical Journal
巻 3,
号 4,
p. 245-252,
発行日 2024-12-25
|
| 記事種別 |
|
|
|
Review |
| 内容記述 |
|
|
内容記述タイプ |
Abstract |
|
内容記述 |
Multiple myeloma (MM) is an incurable hematological malignancy. Introduction of autologous stem cell transplantation, as well as proteasome inhibitors and immunomodulatory drugs (IMiDs) has improved the treatment results. However, many patients develop resistance to existing therapies, and novel treatment strategies for these patients must be established. Therapeutic antibodies including daratumumab or isatuximab targeting CD38 and elotuzumab targeting SLAMF7 have been introduced in the clinic as immunotherapies for MM. These antibodies exert cytotoxic effects on myeloma cells through the activation of effector cells such as natural killer cells and induction of phagocytosis by macrophages. The recent studies suggest the possibility of therapeutic antibodies to bring about influence on testing in treatment of MM. CD38 is one of the antigens used for detection of myeloma cells in flowcytometry. The use of daratumumab is supposed to downregulate CD38 expression in myeloma cells. Thus, daratumumab treatment may affect the evaluation of minimal residual disease (MRD) by flow cytometry. Immunofixation electrophoresis (IFE) to detect monoclonal protein is essential for evaluation of response to treatment. Both daratumumab and elotuzumab are derived from human IgG-k and their administration may affect the evaluation of immunofixation electrophoresis if the tumor-derived M protein belongs to the same IgG-k subclass. To overcome the influence of therapeutic antibodies on testing, a method for detecting MRD using different antibodies from conventional ones and daratumumab-specific immunofixation electrophoresis reflex assay (DIRA) for IFE have been introduced. In this review, progress of therapeutic antibodies and possible impacts of these antibodies on the evaluation of response to the treatment will be discussed. |
|
言語 |
en |
| 出版者 |
|
|
出版者 |
Dokkyo Medical Society |
| ISSN |
|
|
収録物識別子タイプ |
EISSN |
|
収録物識別子 |
2436-522X |
| 書誌レコードID |
|
|
収録物識別子タイプ |
NCID |
|
収録物識別子 |
AA12941861 |
| DOI |
|
|
関連タイプ |
isIdenticalTo |
|
|
識別子タイプ |
DOI |
|
|
関連識別子 |
https://doi.org/10.51040/dkmj.2024-012 |
| 出版タイプ |
|
|
出版タイプ |
VoR |
|
出版タイプResource |
http://purl.org/coar/version/c_970fb48d4fbd8a85 |
DKMJ-3-4-1.pdf (197 KB)
.png)
